Radiotherapy may cause low-grade intestinal inflammation in cancer survivors

Patients who have undergone pelvic radiotherapy may live with low-grade chronic inflammation of the lower intestine 20 years after the treatment. 0

Santhera’s Agamree becomes first approved treatment in UK for all DMD patients – Pharmaceutical Technology

Share this article Santhera’s chief medical officer Shabir Hasham said the company is planning on making Agamree available in the UK in the second half

January 12, 2024

Study highlights oversight in childhood brain injury checks

Almost a quarter of US children with symptoms of a brain injury or concussion are not checked for the condition, with younger children particularly likely

April 26, 2024

Mydecine Announces Conditional Approval of CSE Listing | Psychedelic Invest

Mydecine Innovations Group Inc. (NEO:MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), is pleased to announce that it has made an application and received

August 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.